Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L-Vax + Bacillus Calmette-Guérin + cyclophosphamide
- Development stage
- Preclinical
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Intramuscular, Oral, Intravenous
01
Overview
L-Vax + Bacillus Calmette-Guérin + cyclophosphamide is a combination regimen designed as an investigational cancer immunotherapy. L-Vax refers to an autologous tumor cell vaccine; Bacillus Calmette-Guérin (BCG) is a bacterial immunostimulant often used as an adjuvant to activate immune responses against tumors; cyclophosphamide is a cytotoxic alkylating agent with both antineoplastic and immunosuppressive activities. Cyclophosphamide works by alkylating DNA, causing cross-links and inhibition of tumor cell replication, and modulates the immune system by selective T-cell depletion and cytokine modulation[2][4][6][8]. BCG acts as a non-specific immune adjuvant that enhances the body’s immune response against tumor antigens present in the vaccine component[3][5]. The combination is intended to boost anti-tumor immunity and enhance chemoimmunotherapy efficacy by combining immune activation (BCG, L-Vax) with cytotoxic cell reduction (cyclophosphamide)[1][5].
- Other names
- BCGL-Vax vaccineCytoxan
02
Targets
DNAAutologous dinitrophenyl-modified tumor cell antigensPRR (Pattern recognition receptors)
Beyond the preview
Go deeper on L-Vax + Bacillus Calmette-Guérin + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on L-Vax + Bacillus Calmette-Guérin + cyclophosphamide.